Evidence map›Paper›PMID 41229836›Full record

ArticleJournal of thoracic disease2025

Disease burden of interstitial lung disease and pulmonary sarcoidosis from 1992 to 2021 and prediction of future disease burden trend in China.

Zhiqin Xie, Yunyu Du, Li Zhou, Wanyin Xiong, Min Zhang, Tianxin Xiang, Zhen Yang

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiqin Xie *Jiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yunyu Du *Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Li ZhouJiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Wanyin XiongJiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Min ZhangJiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Tianxin XiangJiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Zhen YangDepartment of Nursing, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevalence of interstitial lung disease (ILD) and pulmonary sarcoidosis (PS) is rising, posing a significant health concern globally and particularly in China. This study aims to elucidate the disease burden of ILD & PS in China and to provide projections of future trends. Methods: This study examined ILD and PS prevalence and mortality rates in China, focusing on variations by age, gender, and time period. Data were obtained from the 2021 Global Burden of Disease (GBD) database. We employed Bayesian age-period-cohort (BAPC) modeling, Joinpoint regression (JPR), and traditional age-period-cohort (APC) analysis to evaluate trends. The age-standardized prevalence rose by 8%, while the overall mortality rate also increased, despite a 2.5% decrease in the age-standardized mortality rate (ASMR). Males consistently exhibited higher death rates than females. Results: ILD and PS prevalence in China increased from 22.17 per 100,000 people in 1992 to 44.17 per 100,000 in 2021, with mortality rates rising from 0.26 to 0.54 per 100,000 in the same period. Projections indicate continued increases in both ILD and PS cases and deaths through 2030. Conclusions: This study highlights the growing ILD and PS burden in China from 1992 to 2021 and anticipates further rises in cases and fatalities over the next decade, even as prevalence rates are expected to stabilize. Age remains a key risk factor.

Indexed as

Disease burdeninterstitial lung disease (ILD)pulmonary sarcoidosis forecasting (PS forecasting)

Identifiers

PMID41229836
PMCPMC12603495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.